Objective: Phlebolymphedema (chronic venous insufficiency-related lymphedema) is a common and costly condition. Nevertheless, there is a dearth of evidence comparing phlebolymphedema therapeutic interventions. This study sought to examine the medical resource utilization and phlebolymphedema-related cost associated with Flexitouch (FLX; Tactile Medical, Minneapolis, Minn) advanced pneumatic compression devices (APCDs) relative to conservative therapy (CONS) alone, simple pneumatic compression devices (SPCDs), and other APCDs in a representative U.S. population of phlebolymphedema patients.
Phlebolymphedema is a vascular condition that results in lower extremity edema from the combined effects of chronic venous insufficiency (CVI) and lymphedema. [1] [2] [3] In the United States, phlebolymphedema is a common and expensive condition. However, the prevalence and direct costs of phlebolymphedema are not well documented, and the condition is widely considered to be underdiagnosed. 1, 4, 5 CVI alone is considered a major public health problem in the United States, and between 3.0% and 11% of the population experience edema and negative skin changes due to CVI. 6 Phlebolymphedema occurs in advanced forms of CVI as a pathophysiologic consequence of venous Health Economics, LLC, Tierra Verde c hypertension and related lymphatic overload. The condition can be aggravated by lymphatic damage from repeated episodes of cellulitis. There is a high incidence of venous leg ulcers (VLUs) among patients with phlebolymphedema driven by the severity of CVI in this population of patients and exacerbated by the edema. VLUs are open wounds that reflect the venous hypertension associated with reflux or obstruction in the venous system. 7 VLUs are estimated to affect >500,000 people annually in the United States, although incidence is not well documented and actual incidence of VLUs may be substantially higher. 8 Because approximately 50% of VLUs recur within 10 years, 9 this chronicity compounds their economic impact and need for repetitive care. In the United States, VLUs result in treatment costs between $2.5 and $3.5 billion and a loss of >2 million workdays annually. 10 A study of the economics of VLU treatment demonstrated an annual average yearly cost per patient of $15,732, which tripled if the VLU failed to heal. 11 In addition, VLUs cause severe debilitation and discomfort of patients, leading to greater rates of absenteeism, 8 with indirect costs that amplify the economic impact.
Patients with phlebolymphedema and patients with VLUs in particular are more difficult to manage than those with lymphedema in the absence of CVI. 2 As such, there is greater urgency for earlier diagnosis and treatment to reduce downstream sequelae of phlebolymphedema, including nonhealing and recurrent VLUs, which can be complicated by cellulitis and septic shock. 2, 12, 13 More aggressive and earlier treatment of CVI is needed to prevent such complications, to reduce hospitalizations, and ultimately to reduce the overall cost of care. 14 The current recommended treatment of phlebolymphedema is compression therapy to reduce tissue edema 2 and, potentially, superficial surgery to treat VLUs. 15 The Effect of Surgery and Compression on Healing and Recurrence (ESCHAR) trial, a randomized controlled trial with >500 patients, showed that the 6-month healing rate for chronic venous ulceration is 65% in both the compression and superficial surgery groups. Treatment of the underlying lymphedema is usually conducted in two phases. The first (reduction) phase consists of "conservative therapy" (CONS), which includes professionally administered manual lymphatic drainage, multilayer bandaging, compression garments, decongestive exercises to reduce edema, preventive skin care, education in self-management, and, for the venous component, wound dressings for an open VLU. Adjunctive treatment during this phase may also include use of a pneumatic compression device (PCD). PCDs assume a major role in the second (maintenance) phase, in which patients optimize the attained edema reduction with home-based treatments. PCDs have been shown to significantly improve lymphatic circulatory function, 16, 17 to reduce edema volume, [18] [19] [20] and to improve patient-reported symptoms and quality of life. 20, 21 Compared with simple PCDs (SPCDs), advanced PCDs (APCDs) provide a greater degree of adjustability and programmability as well as greater degrees of edema reduction. 22 Use of APCDs has been associated with significantly lower rates of cellulitis and outpatient care, 23 hastening of VLU healing, 24 and responsiveness in long-standing
VLUs that resist healing with other methods. [25] [26] [27] However, systematic reviews have not addressed the therapeutic response to pneumatic compression therapy of phlebolymphedema within the context of an economic analysis. 28, 29 Consequently, this study aimed to evaluate which specific phlebolymphedema compression strategy has the greatest potential to reduce both medical resource utilization (MRU) and direct medical costs within a representative privately insured U.S. population of phlebolymphedema patients with >1 year of treatment.
METHODS
Setting and data source. This study used deidentified Health Insurance Portability and Accountability Actcompliant commercial administrative claims data from the Blue Health Intelligence (BHI) research database for the complete years 2012 through 2016. The data set contained longitudinal information captured by commercial health insurance claims. The core BHI databases contain >165 million members of individual Blue Cross Blue Shield plans from across the United States. Study data were accessed by procedures compliant with the Health Insurance Portability and Accountability Act of 1996; therefore, informed consent or Institutional Review Board approval was not required.
Study population.
Patients with a diagnosis of nonfilarial lymphedema were first identified on the basis of one inpatient or two outpatient primary or secondary This study focuses on PCDs rather than on compression garments and compression bandaging, given the dearth of evidence around PCDs and that much research has already been conducted on garments, bandaging, and other modes of static compression. FLX was selected as the particular APCD of interest on the basis of its robust efficacy data 22, 23 and the opportunity to evaluate its impact on MRU and costs in a high-risk phlebolymphedema cohort. In addition, the FLX manufacturer is the sole provider submitting the insurance claims, permitting a unique opportunity to crossmatch provider details (ie, National Provider Identifier number) with device code (ie, HCPCS code E0652).
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Patients' demographic and clinical characteristics. The claims database included information on patients' demographic and socioeconomic characteristics, such as age, sex, commercial insurance type, and census region. In addition, baseline comorbid conditions were identified using the Elixhauser comorbidity index in the 12 months before treatment initiation index date.
Medical resource use and cost. A clinically relevant and broad set of medical resources and costs were defined and evaluated for each patient. The number of cellulitis infections was established by enumerating patients with a primary or a secondary diagnosis code for cellulitis. Additional medical resources included the absolute and mean number of per-patient hospitalizations, the absolute and mean number of per-patient outpatient hospital visits, and the absolute and mean number of patients receiving PT or OT. Costs were calculated per patient per year (PPPY), based on the setting in which they were incurred, including home health, emergency, inpatient, outpatient hospital, outpatient PT or OT, physician's office, laboratory, and other service locations. Prescription and medical equipment costs were not available in this data set. Only phlebolymphedema-and relevant sequelae-related medical resources and costs were considered. Resource use and cost data were designated phlebolymphedema or relevant sequelae related if the corresponding claim had a diagnosis code for primary or secondary lymphedema, cellulitis, ulcers, septic shock, erysipelas, lymphangitis, or other local skin infection.
Statistical analysis. Study groups were matched to control for differences in demographic and clinical characteristics using propensity scores derived from logistic regression. A stepwise model included the following covariates to control for and thus match on: Elixhauser comorbidity index components; age; sex; region of country; insurance type; and dummy indicators for breast cancer, melanoma, uterine cancer, ovarian cancer, prostate cancer, cervical cancer, vaginal cancer, vulvar cancer, lymphoma, soft tissue sarcoma, congestive heart failure, CVI, VLU, diabetes, iliac vein disorders, pulmonary hypertension, and postphlebitic syndrome.
All statistical tests were two sided with a significance level of P < .05. Baseline demographic and clinical characteristics were assessed using c 2 tests for categorical variables and t-tests for continuous variables. Costs were analyzed using a general linear model with gamma distribution and log link while controlling for age and sex. Distribution shape and transformation were assessed by modified Park test and Box-Cox test, respectively. 30 Dichotomous study outcomes (patients with or without an inpatient visit, outpatient visit, use of PT, and cellulitis disease) were assessed using a logistic model that controlled for varying length of follow-up time in which the log of follow-up time was used as an offset term in the model. In addition, to assess the number of inpatient visits, we fitted a Poisson model using the number of events and log transformed follow-up time as an offset variable to account for varying lengths of follow-up. The number of outpatient and PT visits was counted annually starting at the index date and assessed with a general linear model. As study patients had differing lengths of follow-up times, study outcomes were annualized on a PPPY basis. All analyses were undertaken using SAS version 9.4 on a personal computer platform (SAS Institute, Cary, NC).
RESULTS

Study population. The Fig presents the study sample.
A total of 26,902 patients with lymphedema were identified as continuously enrolled with medical benefits for at least 12 months before and 6 months after the index date. Of those, 18,272 patients without a diagnosis for CVI were excluded, leaving 8630 patients with phlebolymphedema (CVI and lymphedema). Next, patients not receiving baseline CONS were excluded from analysis, leaving 1065 patients qualified for inclusion in the study.
Patients were then stratified on the basis of whether they received CONS alone, CONS þ FLX, CONS þ SPCDs, or CONS þ APCDs. The majority of unmatched patients, 860 (80.8%), received CONS only, whereas 87 (8.2%) received CONS þ FLX, 34 (3.2%) received CONS þ SPCDs, and 84 (7.9%) received CONS þ other APCDs. 
DISCUSSION
This study demonstrates the significant opportunity that exists to have an impact on resource utilization and treatment cost of phlebolymphedema through the application of individual treatment strategies. Our data demonstrate a significant difference in phlebolymphedema-and sequelae-related MRU and costs for patients on FLX vs patients on CONS, SPCDs, and other APCDs, listed in order of magnitude of cost differences. Our results support the use of FLX specifically as an adjunct to CONS in this population of higher risk patients. Within the realm of intermittent pneumatic compression, it appears that individual devices can produce significantly different outcomes. To our knowledge, this is the first study to specifically evaluate the impact of alternative compression therapy modalities on MRU and costs, including inpatient, outpatient, and home health costs, in a phlebolymphedema population.
The majority of patients in this study had severe phlebolymphedema, reflected in the high rates of VLUs (89.6%-94.0% of phlebolymphedema patients). Patients with VLUs are generally considered more difficult to treat and are associated with a higher overall cost of treatment than of patients with other stages of CVI. 11 The PPPY phlebolymphedema-and sequelae-related costs associated with CONS, the most common treatment modality, averaged $12,253, which is approximate to the total costs for treating VLUs observed in the study of Ma et al 11 ($15,732 on average, or $10,563 among patients with healed, nonrecurrent VLUs). Notably, the total disease-related costs for treating phlebolymphedema are substantially higher than the diseaserelated costs reported by Karaca-Mandic et al 23 within the broader lymphedema population ($2937). As opposed to the study of Karaca-Mandic et al, which does not control for clinical severity of lymphedema, this study looks at phlebolymphedema, the most severe form of CVI. Within this population of patients with more severe disease, the magnitude of our total cost differential compared with CONS (69% lower costs; P ¼ .001), SPCDs (85% lower costs; P ¼ .008), and other APCDs (53% lower costs; P ¼ .032) is markedly greater than that observed by Karaca-Mandic et al 23 in the broader lymphedema population looking at FLX vs SPCDs. The higher cost associated with phlebolymphedema is often driven by the high cost of treatment for open ulcers, which FLX helps to heal, thereby reducing the economic burden associated with treatment of phlebolymphedema. 31 In this study, cost differences across comparator arms (CONS, SPCDs, and other APCDs) are primarily driven by lower outpatient and inpatient costs. It is well established that diagnosis of phlebolymphedema is associated with greater risk of infections and development of VLUs, 32, 33 which often lead to increased MRU and increased outpatient-and inpatient-related costs. 11 Effective treatment of phlebolymphedema is necessary to reduce the progression of phlebolymphedema and the serious and costly sequelae. This study demonstrates a significant economic benefit associated with FLX in the outpatient hospital setting, where FLX is associated with 55% lower costs vs CONS (P ¼ .027), 84% lower costs vs SPCDs (P ¼ .020), and 57% lower costs vs other APCDs (P ¼ .041). FLX is further associated with 82% lower inpatient costs compared with CONS (P ¼ .003) and 93% Heart failure 6 (7. lower costs compared with SPCDs (P ¼ .002). These lower outpatient and inpatient costs further highlight the effectiveness of FLX in management of phlebolymphedema and related sequelae. In addition, receipt of FLX was associated with 50% lower rates of cellulitis compared with other APCDs, representing a major direct health benefit for FLX over the broader class of APCDs. Cellulitis is a major driver of MRU and both inpatient and outpatient costs in patients with VLUs. Among patients with VLUs, more than two-thirds of hospital admissions were due to cellulitis that was resistant to outpatient treatment and led to a tripling of costs for such patients. 11 Cellulitis also creates a vicious circle in which the episodes of cellulitis damage existing lymphatic vessels, further worsening the lymphedema. 24, 34 Given the high clinical and cost burden of cellulitis and the vicious circle within phlebolymphedema, it is paramount for clinicians to curb cellulitis early. Our study further supports the need for better awareness and diagnosis of phlebolymphedema. Of the 26,902 patients continuously enrolled with lymphedema, only 8630 (32%) had a diagnosis of CVI. This is similar to the study of Muluk et al, 35 in which 27% of lymphedema patients were identified with concurrent CVI. It is well established that CVI and lymphedema are underdiagnosed, and thus it is likely that a number of potentially eligible patients were excluded from observation because they were not properly diagnosed. The small sample sizes in the study treatment arms therefore speak more generally to the widespread underdiagnosis and undertreatment of patients with phlebolymphedema resulting from the lack of awareness of lymphedema as a consequence of CVI. Our study has several limitations. First, claims data sets do not capture or account for compliance with prescribed compression modalities. Thus, compliance of the patient with any of the modalities evaluated is not known, and its impact on the reported outcomes cannot be assessed.
Second, ulcer healing cannot be determined directly from this analysis and is a limitation of an administrative database analysis. The reduced health care costs of FLX, however, can be related to a greater proportion of healed ulcers in the FLX group, as demonstrated by a previous cost analysis. 11 Reduced MRU with a healed venous ulcer is thus associated with decreased cost. Third, this paper focuses on medical benefit claims and does not include pharmaceutical costs. However, a previous study found that pharmaceutical costs related to lymphedema were negligible across groups of patients. 37 Fourth, established codes do not indicate phlebolymphedema disease severity; thus, we could not control for severity of phlebolymphedema in the propensity score matching. However, the advanced stage of the venous component in this cohort is objectively reflected in the >85% of patients with diagnosed VLUs (Table II) .
Fifth, claims data sets include only coded services and do not capture patients' burden and indirect resource utilization. Our paper likely substantially underestimates the overall burden of phlebolymphedema and the broader impact associated with appropriate treatment on nonmedical costs (eg, transportation costs), indirect costs (eg, productivity, absenteeism), and intangible costs (eg, quality of life, psychosocial burden). A broader look at the full burden of phlebolymphedema is warranted in prospective future research.
Finally, the BHI data set used for analysis includes only commercially insured patients. Thus, our results may not be generalizable to patients covered by Medicaid or Medicare.
CONCLUSIONS
Phlebolymphedema constitutes a substantial proportion of lymphedema patients in the United States and a significant cost burden that is still likely understated. Optimizing treatment to reduce costly complications is therefore an important goal. This analysis demonstrates the benefits attributable to FLX, a specific APCD, in reducing MRU and total costs for these patients relative to CONS, SPCDs, and other APCDs. 
